Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL) announced today that the Company has entered into definitive agreements with primarily institutional investors to sell up to 7,416,520 shares of its common stock and warrants to purchase up to 4,449,910 shares of its common stock for gross proceeds of approximately $21.1 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering. The investors have agreed to purchase the shares of common stock and warrants to purchase common stock (together, a "unit") at a negotiated purchase price of $2.845 per unit, each unit consisting of one share and a warrant to purchase 0.6 shares of common stock. The warrants will be exercisable at any time prior to the fifth anniversary of the closing of the transaction. The exercise price of the warrants will be $2.77 per share.

Lazard Capital Markets LLC served as sole placement agent for the offering.

The securities described above are being offered by the Company pursuant to a previously filed registration statement, which was declared effective by the Securities and Exchange Commission (the "SEC") on July 11, 2006. The transaction is expected to close on or about November 7, 2007, subject to customary closing conditions. The Company intends to use the net proceeds from this offering to fund its efforts to obtain FDA approval for its lead drug candidate FavId(R), to prepare for commercial launch of FavId and for other general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Copies of the final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the SEC's website at '/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... succeeded in measuring vibrational motion of a single molecule ... vibration of a single molecule differs from the behaviour ... performed at the University of California, Irvine, where post-doctoral ... as a visiting fellow under professor Vartkess A. Apkarian, ... was lead by Professor Eric O. Potma. The results ...
(Date:8/20/2014)... High performance computing (HPC) will be ... climate and Earth system model to address the ... Eight national laboratories, including Lawrence Livermore , ... Atmospheric Research, four academic institutions and one private-sector ... laboratories include Argonne, Brookhaven, Lawrence Berkeley, Los Alamos, ...
(Date:8/20/2014)... 2014  PAREXEL International Corporation (NASDAQ: PRXL ... the Baird Healthcare Conference in New York.  Ingo ... will be making a presentation on PAREXEL and discussing ... 3, 2014. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3PAREXEL International To Present At Baird Healthcare Conference 2
... Inc., a,privately-held, development-stage pharmaceutical company dedicated to treating,diseases ... defenses, today,announced that the National Institutes of Health ... excess of $850,000. , ... to advance the development of safe and,effective medical ...
... InSightec Ltd.,announced today that cancer patients suffering pain ... have a new online resource for information about,their ... bone metastases, as well as detailed information about ... the U.S., Canada and,Israel to evaluate whether treatment ...
... Who Can Benefit from Vectibix(R) , ... Amgen (Nasdaq: AMGN ) today announced they ... gene as a predictive biomarker in patients with ... receptor (EGFr) antibody Vectibix(R) (panitumumab) with the U.S. Food ...
Cached Biology Technology:Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 2Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 3MyCancerPain.org Launched as Resource for Patients with Painful Bone Metastases 2MyCancerPain.org Launched as Resource for Patients with Painful Bone Metastases 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 2Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 5Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 6Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 7Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 8
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
(Date:8/20/2014)... that acral melanomas the rare type of skin cancer ... distinct from other more common types of skin cancer, according ... Pigment Cell & Melanoma Research . , Acral melanoma ... the feet, nail-beds and other hairless parts of the skin. ... by UV damage from the sun. , The team, from ...
(Date:8/20/2014)... and salty aroma of sunscreen and seawater signals a ... reporting that the idyllic beach vacation comes with an ... and into the sea, they can become toxic to ... main course for many other marine animals. Their study ... Technology . , Antonio Tovar-Sanchez and David Snchez-Quiles point ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... improve its system for ensuring the safety of its ... Academy of Sciences say. Despite having 40% of the ... independent regulatory agency and sufficient staff to keep pace ... article in ACS,s journal Environmental Science & Technology. ...
... The obscure technology used in heated automobile seats, gadgets that ... devices is undergoing a renaissance and could well emerge as ... play other key roles in addressing some of society,s most ... the technology termed thermoelectrics in the current issue ...
... Elser, Argentina,s soaring, glacier-laden peaks, ancient cultures, and criollo ... draw: access to the "last unpolluted aquatic ecosystems on ... Elser and colleague Esteban Balseiro of the Universidad Nacional ... alpine lakes close to San Carlos de Barliloche in ...
Cached Biology News:Fulbright scholar takes ecological theory to Andean heights 2Fulbright scholar takes ecological theory to Andean heights 3
... exciting new chapter to a ... Agilents 7890A GC gives you ... your lab to the next ... performance, including advanced separation capabilities, ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
... CaspaTag™ Pan-Caspase In Situ Assay Kit is ... caspases in cells undergoing apoptosis. The kit ... use in diagnostic or therapeutic procedures. CHEMICON®s ... a novel approach to detect active caspases. ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
Biology Products: